ClinicalTrials.gg
CompletedNCT01677299Updated Sep 20, 2016Results posted

Assessing the PK and Effect on Glucose and GI Hormone Concentrations of Metformin Delayed-Release in Subjects With T2DM

A Phase 1/2 interventional study of EFB0027 (metformin delayed release) and EFB0026 (metformin immediate-release) in Type 2 Diabetes Mellitus, sponsored by Elcelyx Therapeutics, Inc.. Completed at 2 sites in United States. Open to participants aged 19 Years to 70 Years. Per ClinicalTrials.gov, last updated 2016-09-20.

Sponsored by Elcelyx Therapeutics, Inc. · Phase 1/2, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
19 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 3,307 studies in Diabetes Mellitus, Type 2 with a site in United States — 344 open to participants now, 479 under way, 51 of them phase 3. Diabetes Mellitus, Type 2 · United States.

Enrollment
2,378th of 2,960
24 · median 90
Started
2012
with 141 others
Phase 1/2
41 of 3,307
4 open now
Registered
1,320th of 3,307
by date

Among the 3,307 studies in Diabetes Mellitus, Type 2 with a site in United States, this one is the 2,378th largest by enrollment of the 2,960 interventional ones that give a count, is one of 142 that started in 2012, is one of 41 in phase 1/2, and was the 1,320th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

344 of the 3,307 studies in Diabetes Mellitus, Type 2 with a site in United States are open now. Recruiting first, the newest first:

339 more — sign in →

All 344 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 19 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,307 studies in Diabetes Mellitus, Type 2 with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate how EFB0027 and EFB0026 behave in subjects with type 2 diabetes mellitus.

In addition, this study will compare the effects of EFB0027 and EFB0026 on circulating concentrations of glucose and gastrointestinal hormones in subjects with type 2 diabetes mellitus.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
19 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Is 19 to 70 (inclusive) years old at Visit 1 (Screening).
  2. Is diagnosed with Type 2 Diabetes Mellitus with

    • between 6.0 to 9.5% (inclusive) for subjects managing their diabetes with:

      i. Diet and exercise alone, or ii. A stable regimen (minimum of 2 months at Visit 1) of metformin alone, or iii. A stable regimen (minimum of 2 months at Visit 1) of DPP-4 inhibitor alone, OR

    • HbA1c between 6.0 to 8.5% (inclusive) for subjects managing their diabetes with a stable (minimum of 2 months at Visit 1) combination regimen of metformin and DPP-4 inhibitors.
  3. Has serum creatinine below the at Visit 1 and an estimated above 80 using the Crockroft and Gault equation (CrCl = [(140 - age) x body weight in kg] / (serum creatinine x 72) x (0.85 for females) [ref. 3].
  4. Has a (BMI) of 25.0 to 40.0 kg/m\^2 (inclusive) at Screening.
  5. Is male, or is female and meets all of the following criteria:

    • Not breastfeeding
    • Negative pregnancy test result (human chorionic gonadotropin, beta subunit) at Visit 1 (Screening) (not applicable to hysterectomized females)
    • Surgically sterile, , or if of , must practice and be willing to continue to practice appropriate during the entire duration of the study
  6. Has a physical examination with no abnormalities as judged by the investigator.
  7. Ability to understand and willingness to adhere to protocol requirements.
  8. If on chronic thyroid pharmacologic therapy, the dose must be stable for at least 3 months prior to Visit 1 (Screening), and must have thyroid-stimulating hormone (TSH) test result in normal range at Visit 1 (Screening).

Exclusion criteria

Exclusion Criteria:

  1. Has a medical condition that could potentially affect study participation and/or personal well-being, as judged by the investigator, including but not limited to the following conditions:

    • Hepatic disease
    • Renal disease
    • Gastrointestinal disease
    • Endocrine disorder except diabetes
    • Cardiovascular disease
    • Seizure disorder
    • Organ transplantation
    • Chronic infection
  2. Has any chronic disease requiring medication that has been adjusted in the past 90 days (subjects may take acute intermittent over-the-counter medications such as Tylenol, if needed).
  3. Has any drug treatment that affects gastric pH (prescription or over-the-counter), including any antacids or medications such as Rolaids or Pepcid within 2 days of Visit 1 (Screening).
  4. Has had major surgery of any kind within 6 months of Visit 1 (Screening).
  5. Has received a blood transfusion within 6 months of Visit 1 (Screening).
  6. Has a history of >5 kg weight change within 3 months of Visit 1 (Screening).
  7. Has clinical laboratory test (clinical chemistry, hematology, or urinalysis) abnormalities other than those expected in subjects with diabetes and judged by the investigator to be clinically significant at Visit 1 (Screening).
  8. Has physical, psychological, or historical finding that, in the investigator's opinion, would make the subject unsuitable for the study.
  9. Currently abuses drugs or alcohol or has a history of abuse that in the investigator's opinion would cause the individual to be noncompliant with study procedures.
  10. Has donated blood within 2 months of Visit 1 (Screening) or is planning to donate blood during the study.
  11. Has used insulin within 3 months of Visit 1 (Screening).
  12. Has received GLP-1 receptor agonists and/or thiazolidinedione treatment within 6 months of Visit 1 (Screening).
  13. Has known intolerance to metformin.
  14. Has received any drug within 1 month (or five half-lives of the investigational drug, whichever is greater) of Visit 1 (Screening).
  15. Has known allergies or to any component of study treatment.
  16. Is employed by Elcelyx Therapeutics, Inc (that is an employee, temporary contract worker, or designee of the company).
  17. Smokes more than 10 cigarettes per day, 2 cigars per day, or uses more than 1 can of smokeless tobacco per week.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
24 participants (actual)

Study arms

  • Active comparator
    1000 mg EFB0026 (metformin immediate-release)

    BID

    Drug: EFB0026 (metformin immediate-release)

  • Experimental
    1000 mg EFB0027 (metformin delayed-release)

    BID

    Drug: EFB0027 (metformin delayed release)

  • Experimental
    500 mg EFB0027 (metformin delayed-release)

    BID

    Drug: EFB0027 (metformin delayed release)

  • Experimental
    500 mg EFB0026 + 1000 mg EFB0027

    BID

    Drug: EFB0027 (metformin delayed release) · Drug: EFB0026 (metformin immediate-release)

Interventions

  • DrugEFB0027 (metformin delayed release)

    Comparison of enteric-coating to assess effect on PK

    Also known as: Met DR

  • Active comparator

    Also known as: Met IR, metformin, Glucophage

06

What researchers measure

Primary outcomes

  1. Area Under the Curve (0-t) of Plasma Metformin

    Measures from the time of dosing (0 h) to the time of the last quantifiable concentration following dose administration. The dose of study medication was administered at t = -1 min relative to the start time of the standardized breakfast.

    Time frame: Time points at which data were collected to create the area under the curve (0-t) for plasma metformin were: t = -0.08, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, and 11 h relative to the start time of the standardized breakfast.

  2. Change in Fasting Plasma Glucose

    LS mean difference from Baseline (Day 1) to Day 5

    Time frame: Change from Baseline (Day 1) to Day 5

  3. Within Treatment Comparison Based on Ratios of AUCs of GLP-1

    Time frame: Ratio of Day 5 to Baseline

  4. Within Treatment Comparison Based on Ratios of AUCs of PYY

    Time frame: Ratio of Day 5 to Baseline

07

Results

Posted Jun 16, 2014

Participant flow

Participant flow — Overall Study
MilestoneSequence 1: BCADSequence 2: ABDCSequence 3: CDBASequence 4: DACB
Started6666
Completed6355
Not completed0311
Withdrew: Adverse event0210
Withdrew: Withdrawal by subject0101

Outcome measures

PrimaryArea Under the Curve (0-t) of Plasma Metformin

Measures from the time of dosing (0 h) to the time of the last quantifiable concentration following dose administration. The dose of study medication was administered at t = -1 min relative to the start time of the standardized breakfast.

Time frame:
Time points at which data were collected to create the area under the curve (0-t) for plasma metformin were: t = -0.08, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, and 11 h relative to the start time of the standardized breakfast.
Reported as:
Mean · ng*h/mL
Area Under the Curve (0-t) of Plasma Metformin
ng*h/mL1000 mg EFB00261000 mg EFB0027500 mg EFB0027500 mg EFB0026 + 1000 mg EFB0027
Area Under the Curve (0-t) of Plasma Metformin8672 ± 29.74774 ± 29.93842 ± 37.68075 ± 38.6
PrimaryChange in Fasting Plasma Glucose

LS mean difference from Baseline (Day 1) to Day 5

Time frame:
Change from Baseline (Day 1) to Day 5
Reported as:
Least squares mean · mg/dL
Change in Fasting Plasma Glucose
mg/dL1000 mg EFB00261000 mg EFB0027500 mg EFB0027500 mg EFB0026 + 1000 mg EFB0027
Change in Fasting Plasma Glucose-22.5 ± 6.8-19.9 ± 5-16.4 ± 3.8-21.2 ± 4.7
Statistical analysis
  • 1000 mg EFB0026 · Mixed Models Analysis · p = <0.05 · Ls mean diff (day 5 - baseline): -22.5 · 95% CI -37 to -8Change in fasting plasma glucose from Baseline to Day 5 (end of treatment) for treatment A.
  • 1000 mg EFB0027 · Mixed Models Analysis · p = <0.05 · Ls mean diff (day 5 - baseline): -20 · 95% CI -30 to -9Change in fasting plasma glucose from Baseline to Day 5 (end of treatment) for treatment B.
  • 500 mg EFB0027 · Mixed Models Analysis · p = <0.05 · Ls mean diff (day 5 - baseline): -16 · 95% CI -24 to -8Change in fasting plasma glucose from Baseline to Day 5 (end of treatment) for treatment C.
  • 500 mg EFB0026 + 1000 mg EFB0027 · Mixed Models Analysis · p = <0.05 · Ls mean diff (day 5 - baseline): -21 · 95% CI -31 to -11Change in fasting plasma glucose from Baseline to Day 5 (end of treatment) for treatment D.
PrimaryWithin Treatment Comparison Based on Ratios of AUCs of GLP-1
Time frame:
Ratio of Day 5 to Baseline
Reported as:
Least squares mean · none (values are ratios)
Within Treatment Comparison Based on Ratios of AUCs of GLP-1
none (values are ratios)1000 mg EFB00261000 mg EFB0027500 mg EFB0027500 mg EFB0026 + 1000 mg EFB0027
Within Treatment Comparison Based on Ratios of AUCs of GLP-11.87 ± 0.181.62 ± .111.69 ± .151.88 ± .19
Statistical analysis
  • 1000 mg EFB0027 · Mixed Models Analysis · p = <0.05 · Geometric ls mean ration: 1.6 · 95% CI 1.4 to 1.9
  • 1000 mg EFB0026 · Mixed Models Analysis · p = <0.05 · Geo lsmean ratio of (day 5/baseline): 1.9 · 95% CI 1.5 to 2.3
  • 500 mg EFB0027 · Mixed Models Analysis · p = <0.05 · Geo lsmean ratio (day 5/baseline): 1.7 · 95% CI 1.4 to 2.0
  • 500 mg EFB0026 + 1000 mg EFB0027 · Mixed Models Analysis · p = <0.05 · Geo lsmean ratio (day 5/baseline): 1.9 · 95% CI 1.5 to 2.3
PrimaryWithin Treatment Comparison Based on Ratios of AUCs of PYY
Time frame:
Ratio of Day 5 to Baseline
Reported as:
Least squares mean · none (values are ratios)
Within Treatment Comparison Based on Ratios of AUCs of PYY
none (values are ratios)1000 mg EFB00261000 mg EFB0027500 mg EFB0027500 mg EFB0026 + 1000 mg EFB0027
Within Treatment Comparison Based on Ratios of AUCs of PYY1.55 ± .091.38 ± .091.46 ± .061.49 ± .06
Statistical analysis
  • 1000 mg EFB0026 · Mixed Models Analysis · p = <0.05 · Geo lsmean ratio (day 5/baseline): 1.5 · 95% CI 1.4 to 1.8
  • 1000 mg EFB0027 · Mixed Models Analysis · p = <0.05 · Geo lsmean ratio (day 5/baseline): 1.4 · 95% CI 1.2 to 1.6
  • 500 mg EFB0027 · Mixed Models Analysis · p = <0.05 · Geo lsmean ratio (day 5/baseline): 1.5 · 95% CI 1.3 to 1.6
  • 500 mg EFB0026 + 1000 mg EFB0027 · Mixed Models Analysis · p = <0.05 · Geo lsmean ratio (day 5/baseline): 1.5 · 95% CI 1.4 to 1.6

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
1000 mg EFB0026 BID—0/22 (0%)6/22 (27.3%)
1000 mg EFB0027 BID—1/20 (5%)5/20 (25%)
500 mg EFB0027 BID—0/20 (0%)4/20 (20%)
500 mg EFB0026 BID Plus 1000 mg EFB0027 BID—0/21 (0%)10/21 (47.6%)
Most frequent serious events
Most frequent serious events
Event1000 mg EFB0026 BID1000 mg EFB0027 BID500 mg EFB0027 BID500 mg EFB0026 BID Plus 1000 mg EFB0027 BID
Gastrointestinal Stromal TumourNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/221/200/200/21
Most frequent other events
Showing 10 of 19
Most frequent other events
Event1000 mg EFB0026 BID1000 mg EFB0027 BID500 mg EFB0027 BID500 mg EFB0026 BID Plus 1000 mg EFB0027 BID
DiarrhoeaGastrointestinal disorders3/223/202/207/21
NauseaGastrointestinal disorders2/220/200/203/21
DizzinessNervous system disorders3/220/200/200/21
VomitingGastrointestinal disorders2/220/200/200/21
HeadacheNervous system disorders2/221/201/200/21
Abdominal PainGastrointestinal disorders0/220/201/201/21
DyspepsiaGastrointestinal disorders1/220/201/201/21
FatigueGeneral disorders0/220/201/200/21
Pain in ExtremityMusculoskeletal and connective tissue disorders0/221/200/200/21
Gastrointestinal Stromal TumorNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/221/200/200/21

Baseline characteristics

Age, Continuous
Age, Continuous(years)Sequence BCADSequence ABDCSequence CDBASequence DACBTotal
Mean43.2 ± 3.5456.8 ± 7.2249.7 ± 13.9255.3 ± 7.7951.3 ± 9.98
Sex: Female, Male
Sex: Female, Male(Participants)Sequence BCADSequence ABDCSequence CDBASequence DACBTotal
Female233412
Male433212
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Sequence BCADSequence ABDCSequence CDBASequence DACBTotal
American Indian or Alaska Native00000
Asian03003
Native Hawaiian or Other Pacific Islander00000
Black or African American10012
White536519
More than one race00000
Unknown or Not Reported00000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Sequence BCADSequence ABDCSequence CDBASequence DACBTotal
Hispanic or Latino435214
Not Hispanic or Latino231410
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(participants)Sequence BCADSequence ABDCSequence CDBASequence DACBTotal
United States666624
BMI
BMI(kg/mˆ2)Sequence BCADSequence ABDCSequence CDBASequence DACBTotal
Mean34.13 ± 5.45530.67 ± 2.79335.65 ± 2.93532.87 ± 3.64433.33 ± 4.05
eGFR
eGFR(mL/min/1.73 mˆ2)Sequence BCADSequence ABDCSequence CDBASequence DACBTotal
Mean117.94 ± 22.065114.65 ± 21.348107.54 ± 16.64493.43 ± 20.354108.39 ± 21.161
HbA1c
HbA1c(%)Sequence BCADSequence ABDCSequence CDBASequence DACBTotal
Mean7.62 ± 1.2347.33 ± 0.9658.07 ± 1.1026.37 ± .3397.35 ± 1.108

1 further baseline measures are reported on the registry.

08

Study locations

2 sites
  • Celerion, Inc.
    Tempe, Arizona 85283, United States
  • Celerion, Inc.
    Lincoln, Nebraska 68502, United States
09

References and documents

Publications

  • DeFronzo RA, Buse JB, Kim T, Burns C, Skare S, Baron A, Fineman M. Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials. Diabetologia. 2016 Aug;59(8):1645-54. doi: 10.1007/s00125-016-3992-6. Epub 2016 May 23. PubMed 27216492 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2012, a primary completion of Sep 2012 and a completion of Sep 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2014, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2012
First posted
Sep 3, 2012
Start
May 2012
Primary completionActual
Sep 2012
CompletionActual
Sep 2012
Results first posted
Jun 16, 2014
Last update
Sep 20, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 20, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01677299
Lead sponsor
Elcelyx Therapeutics, Inc.
Responsible party
Sponsor
First posted
Sep 3, 2012
Start date
May 2012
Primary completion
Sep 2012
Completion
Sep 2012
Results posted
Jun 16, 2014
Last update
Sep 20, 2016

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methionine

Start the discussion